Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects.
Journal Information
Full Title: Purinergic Signal
Abbreviation: Purinergic Signal
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethical approvalNot applicable. Competing interestsP. Fishman and W. D. Kerns are employed by and are shareholders at Can-Fite BioPharma, Ltd.; S. M. Stemmer and M. H. Silverman are consultants and shareholders at Can-Fite BioPharma; A. Bareket-Samish is a consultant at Can-Fite BioPharma Ltd. Competing interests P. Fishman and W. D. Kerns are employed by and are shareholders at Can-Fite BioPharma, Ltd.; S. M. Stemmer and M. H. Silverman are consultants and shareholders at Can-Fite BioPharma; A. Bareket-Samish is a consultant at Can-Fite BioPharma Ltd."
"Funding The namodenoson research discussed in this review article was funded by the Can-Fite BioPharma Ltd."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025